Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Unveiling the Role of SARS-CoV-2 or mRNA Vaccine Spike Protein in Macrophage Activation Syndrome (MAS)

Author(s): Ziad Fajloun, Layla Tajer, Ziad Abi Khattar and Jean-Marc Sabatier*

Volume 25, Issue 2, 2025

Published on: 22 July, 2024

Article ID: e220724232138 Pages: 5

DOI: 10.2174/0118715265341206240722050403

[1]
Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A european league against rheumatism/american college of rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol 2016; 68(3): 566-76.
[http://dx.doi.org/10.1002/art.39332] [PMID: 26314788]
[2]
Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996; 129(5): 630-2.
[http://dx.doi.org/10.1016/S0022-3476(96)70140-3] [PMID: 8917224]
[3]
Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol 2014; 28(2): 277-92.
[http://dx.doi.org/10.1016/j.berh.2014.03.002] [PMID: 24974063]
[4]
Sheu KM, Hoffmann A. Functional hallmarks of healthy macrophage responses: Their regulatory basis and disease relevance. Annu Rev Immunol 2022; 40(1): 295-321.
[http://dx.doi.org/10.1146/annurev-immunol-101320-031555] [PMID: 35471841]
[5]
Sreejit G, Fleetwood AJ, Murphy AJ, Nagareddy PR. Origins and diversity of macrophages in health and disease. Clin Transl Immunology 2020; 9(12): e1222.
[http://dx.doi.org/10.1002/cti2.1222] [PMID: 33363732]
[6]
Gerfaud-Valentin M, Sève P, Hot A, Broussolle C, Jamilloux Y. Pathophysiology, subtypes, and treatments of adult-onset Still’s disease: An update. Rev Med Interne 2015; 36(5): 319-27.
[http://dx.doi.org/10.1016/j.revmed.2014.10.365]
[7]
Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8(12): 958-69.
[http://dx.doi.org/10.1038/nri2448] [PMID: 19029990]
[8]
Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: Early diagnosis is key. Open Access Rheumatol 2018; 10: 117-28.
[http://dx.doi.org/10.2147/OARRR.S151013] [PMID: 30214327]
[9]
Stabile A, Bertoni B, Ansuini V, La Torraca I, Sallì A, Rigante D. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur Rev Med Pharmacol Sci 2006; 10(2): 53-9.
[PMID: 16705949]
[10]
Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol 2019; 10: 119.
[http://dx.doi.org/10.3389/fimmu.2019.00119] [PMID: 30774631]
[11]
Sharma P, Shreshtha S, Kumar P, Sharma R, Mahapatra TK. A review on macrophage activation syndrome. J Pure Appl Microbiol 2019; 13(1): 183-91.
[http://dx.doi.org/10.22207/JPAM.13.1.19]
[12]
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med 2015; 66(1): 145-59.
[http://dx.doi.org/10.1146/annurev-med-061813-012806] [PMID: 25386930]
[13]
Ravelli A, Davì S, Parodi A. Macrophage activation syndrome: Practice essentials, pathophysiology, etiology. 2024. Available from: https://emedicine.medscape.com/article/1380671-overview?form=login
[14]
Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66(11): 3160-9.
[http://dx.doi.org/10.1002/art.38802] [PMID: 25077692]
[15]
Nierengarten MB. ACR/ARHP annual meeting: Macrophage activation syndrome. 2014. Available from: https://www.the-rheumatologist.org/article/2014-acrarhp-annual-meeting-macrophage-activation-syndrome/
[16]
Cascella M, Rajnik M, Aleem A. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls. Treasure Island, FL: StatPearls Publishing 2024.
[17]
Al-Jamal H, Idriss S, Roufayel R, Abi Khattar Z, Fajloun Z, Sabatier JM. Treating COVID-19 with medicinal plants: Is it even conceivable? A comprehensive review. Viruses 2024; 16(3): 320.
[http://dx.doi.org/10.3390/v16030320] [PMID: 38543686]
[18]
Martínez-García JJ, López-Acosta JR, Arce-Cabrera D, et al. Case report: Multisystem inflammatory syndrome in children associated with COVID-19, macrophage activation syndrome, and incomplete Kawasaki disease. Front Pediatr 2023; 11: 1167828.
[http://dx.doi.org/10.3389/fped.2023.1167828] [PMID: 37138560]
[19]
Abdelgabar A, Elsayed M. A case of delayed COVID-19-related macrophage activation syndrome. J Med Cases 2022; 13(5): 207-11.
[http://dx.doi.org/10.14740/jmc3903] [PMID: 35655624]
[20]
Annweiler C, Cao Z, Wu Y, et al. Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in sars-cov-2-infected patients. Infect Disord Drug Targets 2020; 20(4): 407-8.
[http://dx.doi.org/10.2174/22123989MTA2cNzIlw] [PMID: 32418532]
[21]
El-Arif G, Farhat A, Khazaal S, et al. The renin-angiotensin system: A key role in SARS-COV-2-induced COVID-19. Molecules 2021; 26(22): 6945.
[http://dx.doi.org/10.3390/molecules26226945] [PMID: 34834033]
[22]
El-Arif G, Khazaal S, Farhat A, et al. Angiotensin II type I receptor (AT1R): The gate towards COVID-19-associated diseases. Molecules 2022; 27(7): 2048.
[http://dx.doi.org/10.3390/molecules27072048] [PMID: 35408447]
[23]
Khazaal S, Harb J, Rima M, et al. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27(9): 2903.
[http://dx.doi.org/10.3390/molecules27092903] [PMID: 35566253]
[24]
Sabatier J-M, Fajloun Z, Legros C. COVID-19 and ehlers-danlos syndrome: The dangers of the spike protein of SARS-CoV-2. Infect Disord Drug Targets 2023; 23(3): e040123212375.
[http://dx.doi.org/10.2174/1871526523666230104145108] [PMID: 36600622]
[25]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Why do athletes develop very severe or fatal forms of covid after intense exercise following SARS-CoV-2 infection or Anti-COVID vaccination? Infect Disord Drug Targets 2023; 23(4): e110123212563.
[http://dx.doi.org/10.2174/1871526523666230111104355] [PMID: 36631923]
[26]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. SIBO: The trail of a “New” human pathology associated with multiple severe and disabling COVID-19 and long covid symptoms or induced by the anti-COVID-19 vaccine. Infect Disord Drug Targets 2023; 23(4): e100223213593.
[http://dx.doi.org/10.2174/1871526523666230210162334] [PMID: 36762752]
[27]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Anti-COVID-19 vaccination, COVID-19, and female contraception: The exacerbated risks (Thromboembolism) of the estrogen-progestin pill. Infect Disord Drug Targets 2023; 23(4): e240223214000.
[http://dx.doi.org/10.2174/1871526523666230224094439] [PMID: 36823996]
[28]
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Understanding and relieving of neuropathic disorders in the long COVID. Infect Disord Drug Targets 2023; 23(4): e270223214061.
[http://dx.doi.org/10.2174/1871526523666230227113205] [PMID: 36843369]
[29]
Fajloun Z, Abi Khattar Z, Kovacic H, Sabatier JM. COVID-19 and anti-COVID-19 vaccination: Potential damages to the thyroid gland. Infect Disord Drug Targets 2023; 23(6): e090523216698.
[http://dx.doi.org/10.2174/1871526523666230509112038] [PMID: 37165584]
[30]
Fajloun Z, Wu Y, Cao Z, Kovacic H, Sabatier JM. COVID-19 and alzheimer’s disease: The link finally established. Infect Disord Drug Targets 2023; 23(7): 14-6.
[PMID: 37254552]
[31]
Fajloun Z, Wu Y, Cao Z, Kovacic H, Sabatier JM. COVID-19 and parkinson’s disease: The link also established! Infect Disord Drug Targets 2023.
[PMID: 37340743]
[32]
Fajloun Z, Khattar ZA, Sabatier JM. The intriguing connection between cholestasis and the renin-angiotensin system dysregulation induced by SARS-CoV-2 and/or the vaccinal spike protein. Infect Disord Drug Targets 2024; 24(7): e080324227802.
[http://dx.doi.org/10.2174/0118715265304515240220105152] [PMID: 38465438]
[33]
Tajer L, Paillart JC, Dib H, Sabatier JM, Fajloun Z, Abi Khattar Z. Molecular mechanisms of bacterial resistance to antimicrobial peptides in the modern era: An updated review. Microorganisms 2024; 12(7): 1259.
[http://dx.doi.org/10.3390/microorganisms12071259]
[34]
Fajloun Z, Abi Khattar Z, Sabatier JM. SARS-CoV-2 or vaccinal spike protein can induce mast cell activation syndrome (MCAS). Infect Disord Drug Targets 2024; 24: 1-3.
[PMID: 38693735]
[35]
Fajloun Z, Sabatier JM. The unsuspected role of the renin-angiotensin system (RAS): Could its dysregulation be at the root of all non-genetic human diseases? Infect Disord Drug Targets 2024; 24(1): e140923221085.
[http://dx.doi.org/10.2174/1871526524666230914114524] [PMID: 37711109]

Rights & Permissions Print Cite
Article Metrics
14
1
Wayfinder Image
© 2025 Bentham Science Publishers | Privacy Policy